帕博利珠单抗获FDA优先审评资格】2025年2月26日,美国FDA已接受该公司为重磅免疫疗法Keytruda(帕博利珠单抗)递交的补充生物制品许可申请(sBLA),寻求批准Keytruda作为手术前的新辅助疗法,用于治疗可切除局部晚期头颈部鳞状细胞癌(LA-HNSCC)患者,随后联合标准放疗(有或无顺铂)作为辅助治疗,然后再作为单药进行辅助治疗。FDA...
Head and Neck CancerFinancially poor镧Over the past decades, randomized clinical trials have assessed and validated the concept of larynx preservation. This new concept has obviously modified the treatment algorithm for laryngopharyngeal squamous cell carcinoma. However surgery for larynx and hypopharynx ...
e23275#Background:Multimodal therapy, including definitive radiotherapy (RT) with or without systemic therapy (ST) or surgery followed by adjuvant RT ± ST is typically recommended for patients (pts) with LA HNSCC treated with curative intent. Assessing real-world use of various treatment modalities...
Comparison of carboplatin with 5-fluorouracil (carbo-5FU) versus cisplatin as concomitant chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)' 来自 Semantic Scholar 喜欢 0 阅读量: 28 作者: SH Hanemaaijer,IC Kok,RSN Fehrmann,BVD Vegt,JA Gietema,BEC ...
Associations between OS and EFS were strong (R=0.79-0.88), suggesting EFS is a valid surrogate for OS in surgery ineligible LA HNSCC pts receiving CRT. Legal entity responsible for the study Merck & Co., Inc. Funding Merck & Co., Inc. Disclosure C.M. Black: Financial Interests, Personal...
Abstract CT285: KEYNOTE-689: A phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) 来自 ResearchGate 喜欢 0 阅读量: 359 作者:NY Lee,R Uppaluri,W Westra,EE Cohen,D Adkins ...
339TiPPhase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LU... C.S.,Chan,A.,... - 《Annals of Oncology》...
NBTXR3的适应症是初治局部晚期头颈部鳞状细胞癌(LA-HNSCC)老年受试者。 此药物由Nanobiotix S.A./ 上海联拓生物科技有限公司/ Valdepharm生产并提出实验申请,[实验的目的] 主要目的:评价研究者选择的单独放疗(RT)或联合西妥昔单抗的放疗激活瘤内注射NBTXR3在受试者中
Key eligibility criteria: age ≥18 yrs; ECOG PS of 0 or 1; histologically or cytologically confirmed LA HNSCC; unresected tumor prior to CRT; definitive platinum-based CRT completed ≤24 wks before randomization; no evidence of disease following CRT; unfavorable risk of recurrence (defined as ...
The randomized, global, open-label, phase 3 KEYNOTE-689 trial (NCT03765918) will evaluate the efficacy and safety of neoadjuvant pembro and adjuvant pembro plus SOC in pts with previously untreated resectable LA HNSCC. Trial design Pts will be randomly assigned 1:1 to two arms. In arm A, ...